Suppr超能文献

微量的强效物质:一项关于迷幻剂微剂量服用的访谈研究

Powerful substances in tiny amounts: An interview study of psychedelic microdosing.

作者信息

Johnstad Petter Grahl

机构信息

University of Bergen, Bergen, Norway.

出版信息

Nordisk Alkohol Nark. 2018 Feb;35(1):39-51. doi: 10.1177/1455072517753339. Epub 2018 Feb 15.

Abstract

AIMS

This article presents a qualitative interview study of people who microdose with psychedelic drugs, which means that the user takes about one tenth of an ordinary recreational dose.

DESIGN

Respondents ( = 21) were recruited at several Internet fora for individual interviews via private messaging. Every participant was male, and the median respondent was in his 30s with a stable job and relationship and extensive entheogen experience.

RESULTS

Respondents tended to experiment with microdosing in phases, reporting mostly positive consequences from this form of drug use. Reported effects included improved mood, cognition, and creativity, which often served to counteract symptoms especially from conditions of anxiety and depression. There were also reports of various challenges with psychedelic microdosing, and some did not find the practice worth continuing.

CONCLUSION

The study obtained evidence of a group of users taking small doses of psychedelics not for the purpose of intoxication but to enhance everyday functioning. While the study's findings are not generalisable, they may inform subsequent investigations with research questions and hypotheses.

摘要

目的

本文呈现了一项对使用致幻药物进行微剂量服用者的定性访谈研究,微剂量服用是指使用者服用约为普通娱乐剂量十分之一的药物。

设计

通过私信在几个互联网论坛招募受访者(n = 21)进行个人访谈。每位参与者均为男性,受访者的年龄中位数为30多岁,有稳定的工作和恋爱关系,且有丰富的致幻剂使用经验。

结果

受访者倾向于分阶段尝试微剂量服用,大多报告称这种用药方式带来了积极的效果。报告的效果包括情绪、认知和创造力的改善,这些通常有助于缓解尤其是焦虑和抑郁状况引起的症状。也有关于致幻剂微剂量服用带来各种挑战的报告,一些人认为这种做法不值得继续。

结论

该研究获得了证据,表明有一群使用者服用小剂量致幻剂并非为了 intoxication,而是为了增强日常功能。虽然该研究的结果无法推广,但它们可能为后续研究的问题和假设提供参考。 (注:原文中“intoxication”此处可能有误,推测可能是“intoxicating”,“为了致幻”语义不太符合语境,若为“intoxicating”则可译为“为了产生迷幻效果” )

相似文献

1
Powerful substances in tiny amounts: An interview study of psychedelic microdosing.
Nordisk Alkohol Nark. 2018 Feb;35(1):39-51. doi: 10.1177/1455072517753339. Epub 2018 Feb 15.
2
Self-blinding citizen science to explore psychedelic microdosing.
Elife. 2021 Mar 2;10:e62878. doi: 10.7554/eLife.62878.
3
Microdosing psychedelics: Motivations, subjective effects and harm reduction.
Int J Drug Policy. 2020 Jan;75:102600. doi: 10.1016/j.drugpo.2019.11.008. Epub 2019 Nov 25.
4
The Viability of Microdosing Psychedelics as a Strategy to Enhance Cognition and Well-being - An Early Review.
J Psychoactive Drugs. 2020 Sep-Oct;52(4):300-308. doi: 10.1080/02791072.2020.1761573. Epub 2020 May 2.
5
Cannabis as entheogen: survey and interview data on the spiritual use of cannabis.
J Cannabis Res. 2020 Sep 22;2(1):30. doi: 10.1186/s42238-020-00032-2.
6
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers.
Psychopharmacology (Berl). 2019 Feb;236(2):731-740. doi: 10.1007/s00213-018-5106-2. Epub 2019 Jan 2.
7
Exploring the effect of microdosing psychedelics on creativity in an open-label natural setting.
Psychopharmacology (Berl). 2018 Dec;235(12):3401-3413. doi: 10.1007/s00213-018-5049-7. Epub 2018 Oct 25.
8
Perceived outcomes of psychedelic microdosing as self-managed therapies for mental and substance use disorders.
Psychopharmacology (Berl). 2020 May;237(5):1521-1532. doi: 10.1007/s00213-020-05477-0. Epub 2020 Feb 11.
9
Motives and Side-Effects of Microdosing With Psychedelics Among Users.
Int J Neuropsychopharmacol. 2019 Jul 1;22(7):426-434. doi: 10.1093/ijnp/pyz029.
10
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US.
JAMA Health Forum. 2024 Jun 7;5(6):e241653. doi: 10.1001/jamahealthforum.2024.1653.

引用本文的文献

2
Psychedelics and schizophrenia: a double-edged sword.
Mol Psychiatry. 2025 Feb;30(2):679-692. doi: 10.1038/s41380-024-02743-x. Epub 2024 Sep 18.
3
State Cannabis and Psychedelic Legislation and Microdosing Interest in the US.
JAMA Health Forum. 2024 Jun 7;5(6):e241653. doi: 10.1001/jamahealthforum.2024.1653.
4
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research.
J Psychopharmacol. 2024 Aug;38(8):701-711. doi: 10.1177/02698811241254831. Epub 2024 Jun 14.
5
Unlocking the self: Can microdosing psychedelics make one feel more authentic?
Nordisk Alkohol Nark. 2024 Apr;41(2):142-155. doi: 10.1177/14550725231175353. Epub 2023 May 24.
6
LSD increases sleep duration the night after microdosing.
Transl Psychiatry. 2024 Apr 15;14(1):191. doi: 10.1038/s41398-024-02900-4.
7
Repeated microdoses of LSD do not alter anxiety or boldness in zebrafish.
Sci Rep. 2024 Feb 22;14(1):4389. doi: 10.1038/s41598-024-54676-8.
8
Psychedelic Microdosing among Young Adults from Southern California.
J Psychoactive Drugs. 2024 Feb 10:1-12. doi: 10.1080/02791072.2024.2313684.
9
Trait mindfulness and personality characteristics in a microdosing ADHD sample: a naturalistic prospective survey study.
Front Psychiatry. 2023 Oct 16;14:1233585. doi: 10.3389/fpsyt.2023.1233585. eCollection 2023.
10
Altered states of leadership: mindfulness meditation, psychedelic use, and leadership development.
Front Psychol. 2023 Jul 5;14:1151626. doi: 10.3389/fpsyg.2023.1151626. eCollection 2023.

本文引用的文献

3
The Associations of Naturalistic Classic Psychedelic Use, Mystical Experience, and Creative Problem Solving.
J Psychoactive Drugs. 2016 Nov-Dec;48(5):344-350. doi: 10.1080/02791072.2016.1234090. Epub 2016 Oct 8.
4
Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
Clin Pharmacol Ther. 2017 Feb;101(2):170-172. doi: 10.1002/cpt.457. Epub 2016 Sep 23.
5
Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.
J Psychopharmacol. 2015 Mar;29(3):280-8. doi: 10.1177/0269881114565653. Epub 2015 Jan 13.
6
Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study.
J Psychopharmacol. 2015 Mar;29(3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13.
7
Treating drug dependence with the aid of ibogaine: a retrospective study.
J Psychopharmacol. 2014 Nov;28(11):993-1000. doi: 10.1177/0269881114552713. Epub 2014 Sep 29.
8
Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
J Psychopharmacol. 2014 Nov;28(11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.
9
The diffusion of performance and image-enhancing drugs (PIEDs) on the internet: the abuse of the cognitive enhancer piracetam.
Subst Use Misuse. 2014 Dec;49(14):1849-56. doi: 10.3109/10826084.2014.912232. Epub 2014 May 14.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验